We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Ampronix,  Inc

THERMO FISHER SCIENTIFIC

Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App





Thermo Fisher’s TaqPath COVID-19, Flu A, Flu B Combo Kit Granted FDA Emergency Use Authorization

By HospiMedica International staff writers
Posted on 17 Feb 2021
Print article
Image: TaqPath COVID-19, Flu A, Flu B Combo Kit (Photo courtesy of Thermo Fisher Scientific Inc.)
Image: TaqPath COVID-19, Flu A, Flu B Combo Kit (Photo courtesy of Thermo Fisher Scientific Inc.)
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has been granted emergency use authorization (EUA) by the US Food and Drug Administration (FDA) for the company’s Applied Biosystems TaqPath COVID-19, Flu A, Flu B Combo Kit.

The TaqPath COVID-19, Flu A, Flu B Combo Kit is a real-time PCR test for the detection and differentiation of RNA from the SARS-CoV2, influenza A and influenza B viruses in nasopharyngeal and nasal swabs. The kit helps labs expand their existing COVID-19 testing menu for respiratory samples while maintaining low operational costs and workflow simplicity. The kit includes Applied Biosystems Pathogen Interpretive Software to automatically convert genetic analysis data into a readable report, helping reduce risk of user interpretation error.

"Understanding that the flu season would overlap with surges in COVID-19 infections, Thermo Fisher worked rapidly to develop a new multiplex real-time PCR diagnostic kit for detecting and differentiating SARS-CoV-2, influenza A and influenza B. These are illnesses which can present with similar clinical symptoms, but for which patient management, including quarantining measures, greatly differs," said Mark Smedley, president of Genetic Sciences for Thermo Fisher Scientific. Thermo Fisher. "This new kit offers clinical and public health laboratories a single test to help diagnose and monitor the spread of COVID-19 and the flu."



Print article

Channels

Business

view channel
Illustration

Machine Learning Algorithm Identifies Deteriorating Patients in Hospital Who Need Intensive Care

Researchers have developed a machine learning algorithm that could significantly improve clinicians’ ability to identify hospitalized patients whose condition is deteriorating to the extent that they need... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.